2.2. Endpoints
treatment-emergent adverse events, neutropenia
NEUTROPENIA
Efficacy endpoints assessed in this analysis were annualized severe exacerbation rates over the 52-week treatment period and change from baseline in prebronchodilator FEVSafety was measured in terms of treatment-emergent adverse events (TEAEs) and serious AEs (SAEs) throughout the study. Safety data were evaluated by treatment (dupilumab or placebo) for patients with or without clinically defined treatment-emergent neutropenia (<1,500 cells/